Results 101 to 110 of about 27,184 (256)

Distinct Lipidomic Profiles between People Living with HIV Treated with E/C/F/TAF or B/F/TAF: An Open-Label Prospective Cohort Study

Infectious Diseases and Therapy
Introduction Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) has been increasingly replaced by bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in the treatment of human immunodeficiency virus (HIV) owing to its more ...
Zhikai Wan, Junwei Su, Xueling Zhu, Xiang Liu, Yongzheng Guo, Dairong Xiang, Xiaotang Zhou, Xiaorong Peng, Ran Tao, Qing Cao, Guanjing Lang, Ying Huang, Biao Zhu   +12 more
doaj   +1 more source

Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy

AIDS (London)
Objective: To evaluate the efficacy and safety of 96 weeks of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) treatment in participants switching from dolutegravir (DTG)-based therapy.
C. Orkin, A. Antinori, Jürgen K. Rockstroh, Santiago Moreno-Guillén, C. Martorell, J. Molina, Adriano Lazzarin, F. Maggiolo, Y. Yazdanpanah, Kristen N. Andreatta, Hailin Huang, J. Hindman, Hal Martin, A. Pozniak   +13 more
semanticscholar   +1 more source

Tenofovir alafenamide revisited.

Le infezioni in medicina, 2021
Two Tenofovir pro-drugs are available for the treatment of HIV and HBV infection. Tenofovir Alafenamide (TAF) was clinically developed as a safer alternative to the older Tenofovir Disoproxil Fumarate (TDF) as the latter was consistently found to be associated to proximal renal tubule dysfunction and decrease in bone mineral density (BMD).
openaire   +1 more source

Hepatitis B Management in the Middle East: A Narrative Review of Current Antiviral Treatments

Gastrointestinal Disorders
Introduction: Chronic hepatitis B (CHB) is a significant public health issue worldwide, especially in the Middle East region. Around 8% to 20% of patients with CHB develop cirrhosis, which may progress to hepatocellular carcinoma.
Hannah Beck, Nishaanth Dalavaye, Kalaikshiga Kengadaran, Mosammath Monira Khatun, Ria Hitesh Patel, Taif Al-Rubaye, Laith Alrubaiy   +6 more
doaj   +1 more source

Recent advances in pre-exposure prophylaxis for HIV [PDF]

, 2017
Although pre-exposure prophylaxis (PrEP)-the use of antiretroviral drugs by non-infected people to prevent the acquisition of HIV-is a promising preventive option, important public health questions remain.
Desai, M, Field, N, Grant, R, McCormack, S   +3 more
core   +1 more source

High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre‐existing HIV resistance and suboptimal adherence

Journal of Medical Virology
BRAAVE (NCT03631732), a Phase 3b, multicenter, open‐label US study, demonstrated the efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) among Black individuals with suppressed HIV through 48 weeks. Here, 72‐week resistance,
Kristen N. Andreatta, M. D’Antoni, Silvia Chang, Aiyappa Parvangada, Ross Martin, C. Blair, D. Hagins, Princy N. Kumar, J. Hindman, Hal Martin, C. Callebaut   +10 more
semanticscholar   +1 more source

Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate

AIDS Research and Therapy
Concerns of increased metabolic dysfunction have been heightened for HIV patients on long-term antiretroviral therapy (ART). Among first-line ART agents, Tenofovir alafenamide (TAF) may entail a marked increase in weight compared to Tenofovir disoproxil ...
Hamed Mirmoezzi, Hamid Emadi Koochak, Seyed Ali Dehghan Manshadi, Malihe Hasannezhad, SeyedAhmad SeyedAlinaghi, Kiavash Semnani, Ladan Abbasian, Sara Ghaderkhani   +7 more
doaj   +1 more source

Using a single tablet regimen of darunavir, cobicistat, emcitrabine, and tenofovir alafenamide in virally suppressed HIV-1 patients is an adequate treatment option for controlling HIV [PDF]

, 2021
A clinical decision report using: Orkin C, Molina JM, Negredo E, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine,
Kathuria, Priya
core   +1 more source

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

Journal of Virus Eradication, 2018
Background: Higher plasma tenofovir concentrations are associated with higher risks of renal and bone adverse events. The pharmacokinetic boosters ritonavir (RTV) and cobicistat (COBI) significantly increase plasma area under the curve (AUC ...
Andrew Hill, Sophie L. Hughes, Dzintars Gotham, Anton L. Pozniak   +3 more
doaj   +1 more source

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide

EBioMedicine, 2016
Background: Initiation of antiretroviral therapy (ART) and subsequent virologic suppression reduces immune activation and systemic inflammation. Methods: We examined longitudinal changes in biomarkers of monocyte activation (sCD14, sCD163), and systemic (
Nicholas T. Funderburg, Grace A. McComsey, Manjusha Kulkarni, Tammy Bannerman, Jessica Mantini, Bernadette Thornton, Hui C. Liu, Yafeng Zhang, Qinghua Song, Liang Fang, Jason Dinoso, Andrew Cheng, Scott McCallister, Marshall W. Fordyce, Moupali Das   +14 more
doaj   +1 more source